A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

NCT05996848 on ClinicalTrials.gov · last registry update 2026-01-09

Finished 6 January 2025, after enrolling 300 people. Primary outcome, as filed: CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in body weight. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 300
Started: 2023-08-15
Primary completion: 2025-01-06 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in body weight

Conditions studied

Obesity or Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.